Literature DB >> 31371903

Protective Roles and Mechanisms of Taurine on Myocardial Hypoxia/Reoxygenation-Induced Apoptosis.

Xiaohong Yang1, Jingjing Fu1,2, Huifang Wan3, Zhuoqi Liu1, Lehan Yu3, Bo Yu1, Fusheng Wan1.   

Abstract

BACKGROUND: This study aimed to investigate the protective roles and mechanisms of taurine on myocardial ischemia/reperfusion (I/R)-induced cell apoptosis, and thus provide evidence for the treatment of myocardial I/R injury and the development of related drugs.
METHODS: The cardiomyocytes of neonatal rats were used to prepare the hypoxia/reoxygenation (H/R) injury model; gene transfection and small interfering RNA (siRNA) target gene silencing techniques were performed, along with methyl thiazolyl tetrazolium (MTT) assay to detect cell survival, flow cytometry to detect cell apoptosis, and Western blot to measure protein expressions.
RESULTS: Compared with the H/R group, the apoptosis rates of cardiomyocytes in the three taurine (TAU)-protection groups were significantly decreased (p < 0.05). As the TAU concentration increased, the expression of Bcl-2 protein in H/R cardiomyocytes also gradually increased (p < 0.05), while the protein expressions of p53 up-regulated modulator of apoptosis (PUMA), C/EBP homologous protein (CHOP), Bax, glucose-regulated protein 78kD (GRP78), and caspase-3 gradually decreased (p < 0.01). TAU strongly downregulated the expression of PUMA-transfected cardiomyocytes. After targeted silencing of PUMA, the apoptosis rate was significantly decreased, while the expression of Bcl-2 protein was increased, and that of Bax protein was decreased (p < 0.05).
CONCLUSIONS: TAU significantly inhibited myocardial H/R-induced apoptosis, and the mechanism may be related to a downregulated expression of PUMA.

Entities:  

Keywords:  Apoptosis; Ischemia/reperfusion injury; Myocardium; Taurine

Year:  2019        PMID: 31371903      PMCID: PMC6656967          DOI: 10.6515/ACS.201907_35(4).20181218A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  38 in total

1.  Targeted deletion of Puma attenuates cardiomyocyte death and improves cardiac function during ischemia-reperfusion.

Authors:  Ambrus Toth; John R Jeffers; Philip Nickson; Jiang-Yong Min; James P Morgan; Gerard P Zambetti; Peter Erhardt
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-01-06       Impact factor: 4.733

2.  Contribution of membrane localization to the apoptotic activity of PUMA.

Authors:  Karen S Yee; Karen H Vousden
Journal:  Apoptosis       Date:  2008-01       Impact factor: 4.677

Review 3.  Myocardial ischemia and reperfusion injury.

Authors:  L Maximilian Buja
Journal:  Cardiovasc Pathol       Date:  2005 Jul-Aug       Impact factor: 2.185

4.  PUMA is critical for neonatal cardiomyocyte apoptosis induced by endoplasmic reticulum stress.

Authors:  Philip Nickson; Ambrus Toth; Peter Erhardt
Journal:  Cardiovasc Res       Date:  2006-10-06       Impact factor: 10.787

5.  PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation.

Authors:  Jian Yu; Wen Yue; Bin Wu; Lin Zhang
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

6.  Taurine reduces caspase-8 and caspase-9 expression induced by ischemia in the mouse hypothalamic nuclei.

Authors:  A G Taranukhin; E Y Taranukhina; P Saransaari; I M Djatchkova; M Pelto-Huikko; S S Oja
Journal:  Amino Acids       Date:  2007-02-14       Impact factor: 3.520

7.  p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia-reperfusion.

Authors:  Bin Wu; Wei Qiu; Peng Wang; Hui Yu; Tao Cheng; Gerard P Zambetti; Lin Zhang; Jian Yu
Journal:  Gut       Date:  2006-11-24       Impact factor: 23.059

8.  Progressively developed myocardial apoptotic cell death during late phase of reperfusion.

Authors:  Z Q Zhao; D A Velez; N P Wang; K O Hewan-Lowe; M Nakamura; R A Guyton; J Vinten-Johansen
Journal:  Apoptosis       Date:  2001-08       Impact factor: 4.677

9.  Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome.

Authors:  Tomoka Takatani; Kyoko Takahashi; Yoriko Uozumi; Eriko Shikata; Yasuhiro Yamamoto; Takashi Ito; Takahisa Matsuda; Stephen W Schaffer; Yasushi Fujio; Junichi Azuma
Journal:  Am J Physiol Cell Physiol       Date:  2004-07-14       Impact factor: 4.249

10.  Taurine prevents the ischemia-induced apoptosis in cultured neonatal rat cardiomyocytes through Akt/caspase-9 pathway.

Authors:  Tomoka Takatani; Kyoko Takahashi; Yoriko Uozumi; Takahisa Matsuda; Takashi Ito; Stephen W Schaffer; Yasushi Fujio; Junichi Azuma
Journal:  Biochem Biophys Res Commun       Date:  2004-04-02       Impact factor: 3.575

View more
  5 in total

1.  Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators.

Authors:  Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2020-05       Impact factor: 2.672

2.  MicroRNA-221/222 Mediates ADSC-Exosome-Induced Cardioprotection Against Ischemia/Reperfusion by Targeting PUMA and ETS-1.

Authors:  Tsai-Chun Lai; Tzu-Lin Lee; Yu-Chun Chang; Yu-Chen Chen; Shu-Rung Lin; Shu-Wha Lin; Chi-Ming Pu; Jaw-Shiun Tsai; Yuh-Lien Chen
Journal:  Front Cell Dev Biol       Date:  2020-12-03

3.  Conditioned medium from adipose-derived stem cells attenuates ischemia/reperfusion-induced cardiac injury through the microRNA-221/222/PUMA/ETS-1 pathway.

Authors:  Tzu-Lin Lee; Tsai-Chun Lai; Shu-Rung Lin; Shu-Wha Lin; Yu-Chen Chen; Chi-Ming Pu; I-Ta Lee; Jaw-Shiun Tsai; Chiang-Wen Lee; Yuh-Lien Chen
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 4.  Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2.

Authors:  Fernanda Dos Anjos; Júlia Leão Batista Simões; Charles Elias Assmann; Fabiano Barbosa Carvalho; Margarete Dulce Bagatini
Journal:  J Immunol Res       Date:  2020-12-01       Impact factor: 4.818

5.  In vitro and in vivo study on prevention of myocardial ischemic injury by taurine.

Authors:  Fengyun Ren; Xing Liu; Xiaoxue Liu; Yanli Cao; Lantao Liu; Xingjiang Li; Yingjun Wu; Shudi Du; Guozhong Tian; Jing Hu
Journal:  Ann Transl Med       Date:  2021-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.